"covid-19" MAB therapeutic prototype

Other Transaction IDV Awarded Last action

Contract number
W911QY2190001
Awardee
Awarding agency
Task orders
0

Award facts

Last date to order
Not on record
IDV ceiling
$390,611,351.38
Contracting staff
Funding agency
Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
NAICS code
Not on record
Set-aside
No set-aside
Competition
Competed Broad Agency Announcement
Pricing
Other

Award details come from SAM.gov/FPDS.

About this IDV

Written by GovTribe AI ·

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded an Other Transaction IDV to Astrazeneca Pharmaceuticals LP on October 9, 2020. With a potential value of $390.6 million, this IDV aims to procure a "COVID-19" MAB Therapeutic Prototype.

The IDV seeks to develop monoclonal antibody therapeutics to treat COVID-19. As the funding agency, the Department of the Army Joint PEO Chemical and Biological Defense supports medical countermeasure programs to protect against chemical and biological threats. This IDV furthers those efforts by enlisting private sector innovation through Astrazeneca Pharmaceuticals LP to prototype monoclonal antibody treatments for COVID-19. The IDV structure allows for follow-on task orders or modifications as research progresses, facilitating rapid private sector responses to the pandemic within the Army's medical countermeasures portfolio.

Transactions

Action Obligated Date
Funding Only Action P00012 · Covid-19 action: final DE-obligation. -$45,944,994
Other Administrative Action P00011 · MS 12 stormchaser-mobile units $0
Supplemental Agreement for work within scope P00010 · Covid-19 action the purpose off this modification is to extend MS 03,07 and 11. $0
Other Administrative Action P00009 · Covid-19 action the purpose of this modification is to update the technical POC and AO/as. $0
Change Order P00008 · Covid-19 action MS 12 stormchaser-mobile units -$2,650,000
Other Administrative Action P00007 · Covid-19 rescind hrpas rating. $0
Other Administrative Action P00006 · "covid-19" change otao and document P0004 will not be executed. $0
Supplemental Agreement for work within scope P00005 · "covid-19" cost reduction and revisions to articles 4 and 6. -$36,964,957
Supplemental Agreement for work within scope P00003 · "covid-19" cost definitization -$4,828,697
Other Administrative Action P00002 · "covid-19" clin 0004 and 0008 realignment $0
Other Administrative Action P00001 · "cpvod-19" incorporate hrpas rating $0
Original award $481,000,000
Show all 12

Quick answers

Who was awarded contract W911QY2190001?

W911QY2190001 was awarded to Astrazeneca Pharmaceuticals LP by ACC Aberdeen Proving Ground (Army Contracting Command) on October 9, 2020.

How much is contract W911QY2190001 worth?

W911QY2190001's own ceiling is $390,611,351.

Which agency awarded contract W911QY2190001?

ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911QY2190001, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).

Was contract W911QY2190001 competed?

The extent of competition for W911QY2190001 was competed.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login